Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.
Sellam J, Rivière E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraccioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X.
Sellam J, et al. Among authors: tolusso b.
Arthritis Res Ther. 2016 Dec 13;18(1):294. doi: 10.1186/s13075-016-1190-z.
Arthritis Res Ther. 2016.
PMID: 27964756
Free PMC article.
Clinical Trial.